DrugPatentWatch Database Preview

VIZIMPRO Drug Profile

« Back to Dashboard

Which patents cover Vizimpro, and when can generic versions of Vizimpro launch?

Vizimpro is a drug marketed by Pfizer Inc and is included in one NDA. There are two patents protecting this drug.

This drug has fifty patent family members in forty-two countries.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this compound. Additional details are available on the dacomitinib profile page.

Summary for VIZIMPRO

International Patents:	50
US Patents:	2
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Drug Prices:	Drug price information for VIZIMPRO
DailyMed Link:	VIZIMPRO at DailyMed

Generic Entry Opportunity Date for VIZIMPRO

Constraining patent/regulatory exclusivity:

FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

NDA:

211288

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VIZIMPRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer Inc	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-001	Sep 27, 2018		RX	Yes	No			Y	Y
Pfizer Inc	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-002	Sep 27, 2018		RX	Yes	No
Pfizer Inc	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-001	Sep 27, 2018		RX	Yes	No

International Patents for VIZIMPRO

Country	Document Number	Estimated Expiration
South Korea	20080095915
Japan	2009007363
Ukraine	85706